Ventana MET (SP44) RxDx Assay
Qualitative IHC assay using rabbit monoclonal anti-MET (clone SP44) to detect MET protein expression in FFPE tumor tissue and support MET-targeted treatment decisions.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
VENTANA MET (SP44) RxDx Assay is an FDA-approved, qualitative immunohistochemistry test that uses a rabbit monoclonal anti-MET antibody, clone SP44, to detect MET protein expression in formalin-fixed, paraffin-embedded tumor tissue on VENTANA BenchMark instruments. It classifies samples as MET positive or negative by predefined scoring criteria to help identify patients who may be candidates for MET-directed treatment strategies.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | MET | MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+) | EMRELIS |
IVD Manufacturer
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Order this test
If your organization is connected to Casandra, you can place an electronic order forVentana MET (SP44) RxDx Assay directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.